BioVie Inc. Completes a Successful Registered Direct Offering
BioVie Inc. (NASDAQ: BIVI) recently made a significant announcement regarding its operations. The clinical-stage company, focused on developing pioneering drug therapies for chronic conditions including liver and neurological disorders, has priced a registered direct offering of 1,146,000 shares of its common stock at a market price of $2.83 per share. This move is projected to generate gross proceeds of about $3.2 million, which will aid the company in its further development efforts.
Utilization of Offering Proceeds
The net proceeds from this offering are intended primarily for working capital and general corporate purposes. By utilizing these funds efficiently, BioVie Inc. aims to advance its clinical trials and enhance its operational strategies in the coming months.
Details of the Offering
The registered direct offering, along with a concurrent private placement, is set to close soon, pending customary closing conditions. ThinkEquity has been appointed as the sole placement agent for this offering, ensuring a reputable intermediary for the transaction.
Background on BioVie Inc.
Founded with a vision to tackle critical medical challenges, BioVie Inc. is making strides in developing drug therapies aimed at treating neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and complications stemming from advanced liver disease. The company’s lead drug candidate, bezisterim, is being designed to handle the complexities of neuroinflammation associated with various chronic illnesses. This innovative approach targets specific pathways implicated in diseases, thus aiming to alleviate symptoms and improve quality of life for patients.
Research and Development Focus
BioVie’s specific focus on drugs that inhibit inflammatory processes has garnered attention, especially amidst increasing interest in treatment options for conditions such as Long COVID, where persistent neurological symptoms have become prevalent. Their ongoing studies are geared toward understanding the multifaceted nature of these diseases and how best to manage them through advanced biopharmaceutical interventions.
Phase 3 Clinical Trials for Liver Disease Treatment
In liver disease, BioVie is working with the FDA in its journey to evaluate BIV201, a continuous infusion of terlipressin which is currently under consideration for Phase 3 clinical trials. This drug has achieved FDA Fast Track designation, underscoring its potential significance in reducing complications associated with liver cirrhosis and ascites.
Investor Relations and Contact Information
For any inquiries related to investor relations, Bruce Mackle is serving as the Managing Director at LifeSci Advisors, LLC and is available via email. Similarly, for media inquiries, Melyssa Weible at Elixir Health Public Relations can provide assistance. The company also encourages stakeholders to visit the BioVie website for comprehensive insights into their ongoing projects and upcoming initiatives.
Frequently Asked Questions
What is the recent announcement made by BioVie Inc.?
BioVie Inc. announced a registered direct offering of shares priced at $2.83 to raise approximately $3.2 million.
How does BioVie plan to use the proceeds from the offering?
The net proceeds will primarily be allocated for working capital and general corporate purposes, enhancing their development programs.
Who is the placement agent for the offering?
ThinkEquity has been appointed as the sole placement agent to facilitate the offering process.
What clinical conditions does BioVie focus on?
BioVie focuses on developing therapies for neurological disorders like Alzheimer’s and Parkinson's disease, as well as for advanced liver disease.
How can investors contact BioVie for inquiries?
Investors can reach out to Bruce Mackle from LifeSci Advisors, and media representatives can contact Melyssa Weible from Elixir Health Public Relations.
